Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day)
versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among
asymptomatic carrier of SAR-CoV2 adult Thai population. Both study treatment regimens will
have oral zinc sulfate combination treatment ( 200mg. twice daily). Outcomes include safety
and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase
chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is
planned, with an interim analysis when approximately 50% of cases is enrolled.